Understand the source comparison
Lose Weight After 40 with Peptides: Protocol Comparison
CJC-1295 + Ipamorelin GH secretagogue. Restores pulsatile GH release, increases lipolysis via HSL activation 100–200 mcg each, daily Before bed (aligns with nocturnal GH surge) 4–8% body fat reduction in adults 40–60 Best first-line option for age-related GH d
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- CJC-1295 + Ipamorelin
- GH secretagogue. Restores pulsatile GH release, increases lipolysis via HSL activation
- 100–200 mcg each, daily
- Before bed (aligns with nocturnal GH surge)
- 4–8% body fat reduction in adults 40–60
- Best first-line option for age-related GH decline. Addresses root hormonal cause, not just symptom
- AOD-9604
- Direct lipolytic. Activates beta-3 adrenergic receptors in adipose tissue, bypasses GH pathway
- 300 mcg daily
- Morning, fasted (maximizes lipolysis window)
- 2.6 kg greater fat loss vs placebo (Obesity Research 2004)
- Excellent adjunct to GH secretagogues. Targets stubborn subcutaneous fat resistant to GH alone
- MK 677 (Ibutamoren)
- Oral ghrelin mimetic. Increases GH and IGF-1 by 40–90%, continuous elevation rather than pulsatile
- 12.5–25 mg daily
- Before bed
- 3–6% body fat reduction, significant lean mass gain
- Convenient oral option but causes more water retention than injectable secretagogues. Monitor fasting glucose
- Tesofensine
- Monoamine reuptake inhibitor. Increases metabolic rate 6–10%, reduces appetite via dopamine/norepinephrine
- 0.25–0.5 mg daily
- Morning (avoid evening due to stimulant effect)
- 9.2% body weight reduction vs 2% placebo (Lancet 2008)
- Powerful but requires cardiovascular monitoring. Best reserved for patients who failed GH secretagogue protocols